The overuse and misuse of antimicrobials is complicating the treatment of previously manageable diseases.
In the case of Mycoplasma genitalium (Mgen) infections, the increased use of macrolide-based antibiotics to treat infections has impacted the drug’s effectiveness to treat Mgen.1 Detecting macrolide resistance can reduce the time to cure and prevent ongoing transmission.2
Through a partnership with SpeeDx, a developer of innovative molecular diagnostic solutions, Roche is ushering in a new era of resistance-focused diagnostics.
ResistancePlus® MG, powered by proprietary PlexPCR® technology, is a multiplex real-time PCR assay for the identification of Mycoplasma genitalium and the detection of 5 macrolide resistance markers associated with resistance to azithromycin. Putting the right information in the right hands is essential to optimizing antimicrobial use and ensuring patients get the best care possible.